Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.
Site Search
Showing 21 - 22 of 22 results
News
|
Sept. 2, 2022
|
3 min read
Vertex’s copay assistance changes add an undue burden for people living with an already expensive, challenging lifelong disease.
News
|
Nov. 23, 2022
|
3 min read